Skip to main content

Table 3 Summary of individual treatments utilized over the course of follow-up at MDACC for patients in this series.

From: Malignant head and neck paragangliomas: Is there an optimal treatment strategy?

Treatments, side-effects and responses for patients included in this study
Gender Radiation Chemotherapy
  Received Dose (Gy) Side Effects Response Received Regimen Side Effects Response
F Y 143 Skin sloughing Progression Y CCNU, Adriamycin Alopecia Progression
M N -- -- -- N -- -- --
F Y 55 Otalgia Progression N -- -- --
M Y N/A N/A Progression Y VP-16, Cisplatin N/A Progression
F Y 68 Mucositis Progression Y DTIC, Adriamycin, Mesna, Ifosfamide N/A Progression
F Y N/A N/A Progression Y CDDP, VP-16 None Progression
F Y N/A N/A Regression Y N/A N/A Regression
M Y 90 N/A Progression Y CVAD Febrile neutropenia, N/V Stable
F Y 39 N/A N/A Y CVAD N/A N/A
M Y 60 None Progression Y Adriamycin, Cytoxan, VP-16, Cisplatin, FTI None Progression
F N -- -- -- Y CVAD N/A N/A
M Y N/A N/A Progression N -- -- --
F N -- -- -- N -- -- --
F Y N/A N/A Stable N -- -- --
F Y N/A N/A Progression Y Taxol, Cytoxan, Adriamycin, DTIC None Stable
F Y N/A N/A Progression N -- -- --
F N -- -- -- N -- -- --
F N -- -- -- N -- -- --
F Y N/A Mucositis Progression Y CVAD Alopecia Progression
  1. N/A implies the data are unknown, '-' implies the patients did not receive the therapy. (Summary of abbreviations: CCNU: Lomustine; VP-16: Etoposide; DTIC: Dacarbazine; CDDP: Cisplatin; CVAD: Cyclophosphamide, Vincristine, Doxorubicin, and Dacarbazine; FTI: Farnesyl transferase inhibitor; N/V: Nausea/Vomiting)